Skip to content
To the full analysis

SELLAS Life Sciences Group stock: balance sheet and debt

SLS
$8.03Closing price of 12 Nov 2026MEQIRI Score 35 out of 100

SELLAS Life Sciences Group has a debt to equity ratio of 0.01.

Daily figure as of 13 Nov 2026

Debt / Equity
0.01
Interest coverage
no data
Current ratio
10.72
Cash & equivalents
$71.89M
Total assets
$78.35M
Equity ratio
90.5%
Goodwill
$1.91M
Net debt
−$70.89M
More cash than debt

Total assets and equity ratio

How large the balance sheet of SELLAS Life Sciences Group, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$2Knot reported separatelynot reported separately100.0%−$2K
2007$12.15Mnot reported separatelynot reported separately89.1%−$11.72M
2008$10.36Mnot reported separatelynot reported separately86.6%−$9.84M
2009$6.25Mnot reported separatelynot reported separately11.9%−$5.6M
2010$7.48Mnot reported separatelynot reported separately32.5%−$6.82M
2011$30.97M$18.76M$5.9M32.7%−$10.87M
2012$54.99M$18.76M$5.9M50.5%−$35.43M
2013$87.98M$33.74M$5.9M6.7%−$37.86M
2014$80.49M$50.82M$6.07M46.0%−$15.25M
2015$82.14M$28.02M$5.9M16.5%−$24.99M
2016$65.81M$28.02M$5.9M43.5%−$1.69M
2017$33.53M$19.51M$1.91M6.2%$8.67M
2018$16.92M$10.41M$1.91M31.0%−$5.34M
2019$16.61M$7.61M$1.91M36.7%−$7.06M
2020$46.05M$7.61M$1.91M60.7%−$34.31M
2021$26.43M$1.91M$1.91M77.0%−$20.65M
2022$20.94M$1.91M$1.91M23.2%−$16.18M
2023$6.22M$1.91M$1.91M−128.3%−$1.62M
2024$19.43M$1.91M$1.91M48.7%−$12.89M
2025$78.35M$1.91M$1.91M90.5%−$70.89M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$2K$2K$00
2007$11.72M$10.82M$00
2008$9.86M$8.97M$21K0
2009$5.68M$741K$88K0.12
2010$6.89M$2.43M$71K0.03
2011$11.43M$10.11M$567K0.06
2012$35.49M$27.76M$57K0
2013$47.79M$5.89M$9.92M1.69
2014$23.65M$37.06M$8.4M0.23
2015$29.73M$13.51M$4.74M0.35
2016$18.08M$28.66M$16.4M0.57
2017$2.32M$2.07M$10.99M5.31
2018$5.34M$5.25M$00
2019$7.28M$6.09M$217K0.04
2020$35.3M$27.96M$991K0.04
2021$21.46M$20.35M$808K0.04
2022$17.13M$4.85M$945K0.19
2023$2.53M−$7.98M$906K−0.11
2024$13.89M$9.47M$1M0.11
2025$71.89M$70.87M$1M0.01

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2009)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy